{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:27:26Z","timestamp":1786980446926,"version":"build-2736575974"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003339","name":"Consejo Superior de Investigaciones Cient\u00edficas","doi-asserted-by":"publisher","award":["JAEINT_22_00028"],"award-info":[{"award-number":["JAEINT_22_00028"]}],"id":[{"id":"10.13039\/501100003339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000921","name":"European Cooperation in Science and Technology","doi-asserted-by":"publisher","award":["CA17120"],"award-info":[{"award-number":["CA17120"]}],"id":[{"id":"10.13039\/501100000921","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Instituto Andaluz de Ciencias de la Tierra"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Model"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Lenalidomide (LEN) is used for the treatment of myeloma blood cancer disease. It has become one of the most efficient drugs to halt this disease. LEN is a low-soluble drug in aqueous media. The search of a pharmaceutical preparation to improve the bioavailability and, therefore, to optimize its efficiency is an important issue for pharmaceutical industries and health care. The use of natural excipients such as montmorillonite (MNT) can provide changes in the physical\u2013chemical properties for improving the bioavailability of this drug. We present the first computational study at the atomic scale of the periodic crystal forms of the polymorphs for this anticancer drug, highly demanded in the pharmacy market. In addition, we propose a pharmaceutical preparation by intercalation of LEN in natural MNT. So, our calculations predict that LEN can be intercalated in the interlayer space of MNT, and be released in aqueous media, and physiological aqueous media in consequence. This release process is a more exothermic reaction than the unpacking energy of any of its polymorphs. Besides, the infrared spectra of the LEN molecule and its crystal polymorphs, and LEN intercalated in the confined space of MNT, have been calculated at different levels of theory. The band frequencies have been assigned, matching with the experimental bands, predicting the use of this technique for experimental studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>\n                      In this work, the method is aimed to explore this research at the atomic and molecular level by using computational modelling methods including INTERFACE FF and other FF along with quantum mechanical calculations (Dmol\n                      <jats:sup>3<\/jats:sup>\n                      and CASTEP) of 3-D periodical systems applying periodical boundary conditions. Models of the isolated molecule and two polymorphs of the crystal structures, with the model of bulk water and LEN intercalated in the MNT model, have been considered. An analysis of the intermolecular interactions is accomplished.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00894-024-06210-w","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T05:55:08Z","timestamp":1733291708000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Intercalation of the anticancer drug lenalidomide into montmorillonite for bioavailability improvement: a computational study"],"prefix":"10.1007","volume":"31","author":[{"given":"Yumeida V.","family":"Meruvia-Rojas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Molina-Montes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Hern\u00e1ndez-Laguna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Ignacio","family":"Sainz-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,4]]},"reference":[{"key":"6210_CR1","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1365-2710.2008.00920.x","volume":"33","author":"X Armoiry","year":"2008","unstructured":"Armoiry X, Aulanger G, Facon T (2008) Lenalidomide in the treatment of multiple myeloma: a review. J Clin Pharma Therapeutics 33:219\u2013226","journal-title":"J Clin Pharma Therapeutics"},{"key":"6210_CR2","doi-asserted-by":"crossref","unstructured":"Kotla V, Goel S, Nitchal S, Heuk C, Vivek K, Das B, Verma A (2009) Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2:36 (10 pags)","DOI":"10.1186\/1756-8722-2-36"},{"key":"6210_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.exphem.2020.09.196","volume":"91","author":"S Martinez-Hoyer","year":"2020","unstructured":"Martinez-Hoyer S, Karsan A (2020) Mechanism of lenalidomide sensitivity and resistance. Exp Hematol 91:22\u201331","journal-title":"Exp Hematol"},{"key":"6210_CR4","unstructured":"Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Pi\u00f1eros M, Znao A, Soerjomataram I, Bray F (2020) Global cancer observatory: cancer today. Lyon, France: International Agency for Research on Cancer"},{"key":"6210_CR5","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394\u2013424","journal-title":"CA Cancer J Clin"},{"key":"6210_CR6","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1634\/theoncologist.2020-0141","volume":"25","author":"H Ludwig","year":"2020","unstructured":"Ludwig H, Durie SN, Meckl A, Hinke A, Durie B (2020) Multiple myeloma incidence and mortality around the globe; interrelations between health access and quality, economic resources, and patient empowerment. Oncologist 25:1406\u20131413","journal-title":"Oncologist"},{"key":"6210_CR7","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","volume":"374","author":"P Moreau","year":"2016","unstructured":"Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L et al (2016) Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 374:1621\u20131634","journal-title":"N Engl J Med"},{"key":"6210_CR8","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1200\/JCO.2017.76.5032","volume":"36","author":"DS Siegel","year":"2018","unstructured":"Siegel DS, Dimopoulos MA, Ludwig H, Facon T, Goldschmidt H, Jakubowiak A, San Miguel J, Obreja M, Blaedel J, Stewart AK (2018) Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol 36:728\u2013734","journal-title":"J Clin Oncol"},{"key":"6210_CR9","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.3324\/haematol.2018.194282","volume":"103","author":"MA Dimopoulos","year":"2018","unstructured":"Dimopoulos MA, San-Miguel J, Belch A, White D, Benboubker L, Cook G, Leiba M, Morton J, Joy Ho P, Kim K, Takezako N, Moreau P, Kaufman JL, Sutherland HJ, Lalancette M, Magen H, Lida S, Seok Kim J, Miles Prince H, Cochrane T, Oriol A, Bahlis NJ, Chair A, O\u2019Rourke L, Wu K, Checter JM, Casneuf T, Chiu C, Soong D, Kate Sasser A, Khkhar NZ, Avet-Loiseau H, Usmani SZ (2018) Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. Haematologica 103:2088\u20132096","journal-title":"Haematologica"},{"key":"6210_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3892\/mco.2023.2705","volume":"20","author":"C-W Zhang","year":"2024","unstructured":"Zhang C-W, Wang Y-N, Ge X-L (2024) Lenalidomide use in multiple myeloma (Review). Mol Clin Oncol 20:7","journal-title":"Mol Clin Oncol"},{"key":"6210_CR11","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s40262-016-0432-1","volume":"56","author":"N Chen","year":"2017","unstructured":"Chen N, Zhou S, Palmisano M (2017) Clinical pharmacokinetics and pharmacodynamics of lenalidomide. Clin Pharmacokinet 56:139\u2013152","journal-title":"Clin Pharmacokinet"},{"key":"6210_CR12","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s00280-016-3228-y","volume":"79","author":"B Guglieri-L\u00f3pez","year":"2017","unstructured":"Guglieri-L\u00f3pez B, P\u00e9rez-Pitarch A, Moes DJAR, Porta-Oltra B, Climente-Mart\u00ed M, Guchelaar HJ, Merino-Sanju\u00e1n M (2017) Population pharmacokinetics of lenalidomide in multiple myeloma patients. Cancer Chemother Pharmacol 79:189\u2013200","journal-title":"Cancer Chemother Pharmacol"},{"key":"6210_CR13","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1021\/acs.cgd.6b01462","volume":"17","author":"R Chennuru","year":"2017","unstructured":"Chennuru R, Muthudoss P, Voguri RS, Ramakrishnan S, Vishweshwar P, Chandra Babu RC, Mahapatra S (2017) Iso-structurality induced solid phase transformations: a case study with lenalidomide. Cryst Growth Design 17:612\u2013628","journal-title":"Cryst Growth Design"},{"key":"6210_CR14","doi-asserted-by":"crossref","unstructured":"Ravikumar K, Sridhar B (2009) Lenalidomide, an antineoplastic drug, and its hemihydrate. Act Crystallogr C65:o502-505","DOI":"10.1107\/S0108270109033642"},{"key":"6210_CR15","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3390\/pharmaceutics12040298","volume":"12","author":"N Avramovi\u0107","year":"2020","unstructured":"Avramovi\u0107 N, Mandi\u0107 B, Savi\u0107-Radojevi\u0107 A, Simi\u0107 T (2020) Polymeric nanocarriers of drug delivery systems in cancer therapy. Pharmaceutics 12:298","journal-title":"Pharmaceutics"},{"key":"6210_CR16","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.smaim.2020.05.002","volume":"1","author":"Z Shi","year":"2020","unstructured":"Shi Z, Zhou Y, Fan T, Lin Y, Zhang H, Mei L (2020) Inorganic nano carriers based smart drug delivery systems for tumor therapy. Smart Mater Med 1:32\u201347","journal-title":"Smart Mater Med"},{"key":"6210_CR17","first-page":"10923","volume":"13","author":"E Pancani","year":"2023","unstructured":"Pancani E, Veclani D, Agnes M, Mazza A, Venturini A, Malanga M, Manet I (2023) Three-in-one: exploration of cabazitaxel, bicalamutamide and chlorin e6 in new mixed cyclodextrin-crosslinked polymers. Royal Soc Chem Adv 13:10923","journal-title":"Royal Soc Chem Adv"},{"key":"6210_CR18","doi-asserted-by":"publisher","first-page":"117762","DOI":"10.1016\/j.molliq.2021.117762","volume":"344","author":"H Harati","year":"2021","unstructured":"Harati H, Morsali A, Bozorgmehr MR, Beyramabadi SA (2021) \u03b2-cyclodextrin-lenalidomide anticancer drug delivery nanosystem: a quantum chemical approach. J Mol Liquids 344:117762","journal-title":"J Mol Liquids"},{"key":"6210_CR19","doi-asserted-by":"crossref","unstructured":"Thandapani Gomathi, C. Govindarajan, Maximas H. Rose HR, Sudha PN, Imran PKM, Venkatesan J, Kim S-K (2014) Studies on drug-polymer interaction, in vitro release and cytotoxicity from chitosan particles excipient. Int J Pharm 468:214\u2013222","DOI":"10.1016\/j.ijpharm.2014.04.026"},{"key":"6210_CR20","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.3390\/cancers12113144","volume":"12","author":"D Iannazzo","year":"2020","unstructured":"Iannazzo D, Ettari R, Giofr\u00e8 S, Eid AH, Bitto A (2020) Recent advances in nanotherapeutics for multiple myeloma. Cancers 12:3144","journal-title":"Cancers"},{"key":"6210_CR21","doi-asserted-by":"crossref","unstructured":"Karri VVSR, Dhandapani NV, Mannemala SS, Radhakrishna K, Mulukutla S, Sudunagunta D (2017) Ameliorating the antitumor activity of lenalidomide using PLGA nanoparticles for the treatment of multiple myeloma. Braz J Pharm Sci 53(2):e15185","DOI":"10.1590\/s2175-97902017000215185"},{"key":"6210_CR22","doi-asserted-by":"publisher","first-page":"14961","DOI":"10.1039\/C7CP02300F","volume":"19","author":"E Escamilla-Roa","year":"2017","unstructured":"Escamilla-Roa E, Huertas FJ, Hern\u00e1ndez-Laguna A, Sainz-D\u00edaz CI (2017) A DFT study of the adsorption of glycine in the interlayer space of montmorillonite. Phys Chem Chem Phys 19:14961\u201314971","journal-title":"Phys Chem Chem Phys"},{"key":"6210_CR23","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.xphs.2022.10.024","volume":"112","author":"C Soriano-Correa","year":"2023","unstructured":"Soriano-Correa C, P\u00e9rez de la Luz A, Sainz-D\u00edaz CI (2023) Adsorption of capsaicin into the nanoconfined interlayer space of montmorillonite by DFT calculations. J Pharm Sci 112:798\u2013807","journal-title":"J Pharm Sci"},{"key":"6210_CR24","doi-asserted-by":"publisher","first-page":"914","DOI":"10.3390\/pharmaceutics12100914","volume":"12","author":"A Borrego-S\u00e1nchez","year":"2020","unstructured":"Borrego-S\u00e1nchez A, S\u00e1nchez-Espejo R, Garc\u00eda-Vill\u00e9n F, Viseras C, Sainz-D\u00edaz CI (2020) Praziquantel\u2013clays as accelerated release systems to enhance the low solubility of the drug. Pharmaceutics 12:914","journal-title":"Pharmaceutics"},{"key":"6210_CR25","doi-asserted-by":"publisher","first-page":"575","DOI":"10.3390\/pharmaceutics15020575","volume":"15","author":"E Moreno-Dom\u00ednguez","year":"2023","unstructured":"Moreno-Dom\u00ednguez E, Borrego-S\u00e1nchez A, S\u00e1nchez-Espejo R, Viseras C, Sainz-D\u00edaz CI (2023) Experimental and computational study for the design of sulfathiazole dosage form with clay mineral. Pharmaceutics 15:575","journal-title":"Pharmaceutics"},{"key":"6210_CR26","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s10847-020-00978-z","volume":"96","author":"A Mokhtar","year":"2020","unstructured":"Mokhtar A, Bennabi F, Abdelkrim S, Sardi A, Boukoussa B, Souna A, Bengueddach A, Sassi M (2020) Evaluation of intercalated layered materials as an antimicrobial and drug delivery system: a comparative study. J Inclusion Phenomena Macrocyclic Chem 96:353\u2013364","journal-title":"J Inclusion Phenomena Macrocyclic Chem"},{"key":"6210_CR27","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1080\/17425247.2021.1862792","volume":"18","author":"J Dong","year":"2020","unstructured":"Dong J, Cheng Z, Tan S, Zhu Q (2020) Clay nanoparticles as pharmaceutical carriers in drug delivery systems. Expert Opin Drug Deliv 18:695\u2013714","journal-title":"Expert Opin Drug Deliv"},{"key":"6210_CR28","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s00269-003-0324-4","volume":"30","author":"CI Sainz-D\u00edaz","year":"2003","unstructured":"Sainz-D\u00edaz CI, Palin EJ, Hern\u00e1ndez-Laguna A, Dove MT (2003) Octahedral cation ordering of illite and smectite. Theoretical exchange potential determination and Monte Carlo simulations. Phys Chem Miner 30:382\u2013392","journal-title":"Phys Chem Miner"},{"key":"6210_CR29","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1021\/acs.jpcc.6b12467","volume":"121","author":"M Francisco-M\u00e1rquez","year":"2017","unstructured":"Francisco-M\u00e1rquez M, Soriano-Correa C, Sainz-D\u00edaz CI (2017) Adsorption of sulfonamides on phyllosilicate surfaces by molecular modeling calculations. J Phys Chem C 121:2905\u20132914","journal-title":"J Phys Chem C"},{"key":"6210_CR30","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1346\/CCMN.2010.0580208","volume":"58","author":"F Nieto","year":"2010","unstructured":"Nieto F, Mellini M, Abad I (2010) The role of H3O+ in the crystal structure of illite. Clays Clay Miner 58:238\u2013246","journal-title":"Clays Clay Miner"},{"key":"6210_CR31","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2138\/am.2010.3273","volume":"95","author":"J Ortega-Castro","year":"2010","unstructured":"Ortega-Castro J, Hern\u00e1ndez-Haro N, Dove MT, Hern\u00e1ndez-Laguna A, Sainz-D\u00edaz CI (2010) Density functional theory and Monte Carlo study of octahedral cation ordering of Al\/Fe\/Mg cations in dioctahedral 2:1 phyllosilicates. Am Mineral 95:209\u2013220","journal-title":"Am Mineral"},{"key":"6210_CR32","doi-asserted-by":"crossref","unstructured":"Heinz H, Lin T-J, Kishore Mishra R, Emami FS (2013) Thermodynamically consistent force fields for the assembly of inorganic, organic, and biological nanostructures: the INTERFACE force field. Langmuir 29:1754\u20131765","DOI":"10.1021\/la3038846"},{"key":"6210_CR33","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jmgm.2014.01.008","volume":"49","author":"R Martos-Villa","year":"2014","unstructured":"Martos-Villa R, Mata MP, Sainz-D\u00edaz CI (2014) Characterization of CO2 and mixed methane\/CO2 hydrates intercalated in smectites by means of atomistic calculations. J Mol Graph Model 49:80\u201390","journal-title":"J Mol Graph Model"},{"key":"6210_CR34","doi-asserted-by":"publisher","first-page":"7338","DOI":"10.1021\/jp980939v","volume":"102","author":"H Sun","year":"1998","unstructured":"Sun H (1998) COMPASS: an ab initio force-field optimized for condensed-phase applications. Overview with details on alkane and benzene compounds. J Phys Chem B 102:7338\u20137364","journal-title":"J Phys Chem B"},{"key":"6210_CR35","unstructured":"Biovia (2020) Materials Studio, Dassault Systems"},{"key":"6210_CR36","doi-asserted-by":"publisher","first-page":"3358","DOI":"10.1021\/j100161a070","volume":"95","author":"AK Rapp\u00e9","year":"1991","unstructured":"Rapp\u00e9 AK, Goddard WA (1991) Charge equilibration for molecular dynamics simulations. J Phys Chem 95:3358\u20133363","journal-title":"J Phys Chem"},{"key":"6210_CR37","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1016\/0040-4020(80)80168-2","volume":"36","author":"J Gasteiger","year":"1980","unstructured":"Gasteiger J, Marsili M (1980) Iterative partial equalization of orbital electronegativity\u2014a rapid access to atomic charges. Tetrahedron 36:3219\u20133228","journal-title":"Tetrahedron"},{"key":"6210_CR38","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/jcc.540110404","volume":"11","author":"BH Besler","year":"1990","unstructured":"Besler BH, Merz KM Jr, Kollman PA (1990) Atomic charges derived from semiempirical methods. J Comput Chem 11:431\u2013439","journal-title":"J Comput Chem"},{"key":"6210_CR39","doi-asserted-by":"publisher","first-page":"155125","DOI":"10.1103\/PhysRevB.66.155125","volume":"66","author":"B Delley","year":"2002","unstructured":"Delley B (2002) Hardness conserving semilocal pseudopotentials. Phys Rev B 66:155125","journal-title":"Phys Rev B"},{"key":"6210_CR40","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1103\/PhysRevLett.77.3865","volume":"77","author":"JP Perdew","year":"1996","unstructured":"Perdew JP, Burke K, Ernzerhof M (1996) Generalized gradient approximation made simple. Phys Rev Lett 77:3865\u20133868","journal-title":"Phys Rev Lett"},{"key":"6210_CR41","doi-asserted-by":"publisher","first-page":"205414","DOI":"10.1103\/PhysRevB.80.205414","volume":"80","author":"ER McNellis","year":"2009","unstructured":"McNellis ER, Meyer J, Karsten Reuter K (2009) Azobenzene at coinage metal surfaces: role of dispersive van der Waals interactions. Phys Rev B 80:205414","journal-title":"Phys Rev B"},{"key":"6210_CR42","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1088\/0953-8984\/14\/11\/301","volume":"14","author":"MD Segall","year":"2002","unstructured":"Segall MD, Lindan PJD, Probert MJ, Pickard CJ, Hasnip PJ, Clark SJ (2002) First-principles simulation: ideas, illustrations and the CASTEP code. J Phys Condens Matter 14:2717\u20132744","journal-title":"J Phys Condens Matter"},{"key":"6210_CR43","doi-asserted-by":"publisher","first-page":"155114","DOI":"10.1103\/PhysRevB.73.155114","volume":"73","author":"K Refson","year":"2006","unstructured":"Refson K, Clark SJ, Tulip PR (2006) Variational density functional perturbation theory for dielectrics and lattice dynamics. Phys Rev B 73:155114","journal-title":"Phys Rev B"},{"key":"6210_CR44","doi-asserted-by":"publisher","first-page":"105774","DOI":"10.1016\/j.clay.2020.105774","volume":"197","author":"A Borrego-S\u00e1nchez","year":"2020","unstructured":"Borrego-S\u00e1nchez A, Viseras C, Sainz-D\u00edaz CI (2020) Molecular interactions of praziquantel drug with nanosurfaces of sepiolite and montmorillonite. Appl Clay Sci 197:105774","journal-title":"Appl Clay Sci"}],"container-title":["Journal of Molecular Modeling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00894-024-06210-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00894-024-06210-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00894-024-06210-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T14:32:11Z","timestamp":1736951531000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00894-024-06210-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,4]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["6210"],"URL":"https:\/\/doi.org\/10.1007\/s00894-024-06210-w","relation":{},"ISSN":["1610-2940","0948-5023"],"issn-type":[{"value":"1610-2940","type":"print"},{"value":"0948-5023","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,4]]},"assertion":[{"value":"19 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"5"}}